Last reviewed · How we verify
NCT03090113: SPACE
Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
Phase 4 trial testing Shuxuetong Injection in Embolic Stroke in 2,416 participants. Completed in 21 June 2019.
30 March 2019
Quick facts
| Lead sponsor | Beijing Tiantan Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 2,416 |
| Start date | 12 May 2017 |
| Primary completion | 30 March 2019 |
| Estimated completion | 21 June 2019 |
| Sites | 48 locations across China |
Drugs / interventions tested
- Shuxuetong Injection — full drug profile →
- Placebo Injection
Conditions studied
- Embolic Stroke — all drugs for Embolic Stroke →
Sponsor
Beijing Tiantan Hospital
Who can join
Adults 18 to 80, any sex, with Embolic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double blind, placebo-controlled, parallel, multicenter research in order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or asymptomatic new cerebral infarction within 10 days. Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential causes of Embolic Stroke of Undetermined Source (ESUS).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial: rationale and design.
Gu HQ, Xie XW, Jing J, Meng X, et al · · 2020 · cited 9× · PMID 32994371 · DOI 10.1136/svn-2019-000293 -
Ischemic stroke and intervention strategies based on the timeline of stroke progression: Review and prospects.
Xu A, Zhang H, Zhang Y, Wu J, et al · · 2025 · cited 5× · PMID 41049732 · DOI 10.1016/j.apsb.2025.07.026
Verify or expand the search:
- PubMed search for NCT03090113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Shuxuetong Injection
Trials testing the same drug.
- NCT06018181 — Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice · completed
Other Beijing Tiantan Hospital trials
Trials by the same sponsor.
- NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
- NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
- NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
- NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03090113 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
- Last refreshed: 22 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing